Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

Table 1 Fold change and adjusted P values for comparison of genes compared in tissues from patients with disease and from healthy controls (see Fig. 1)

	CD38		IGJ		TNFSF13B		XBP1		IRF4		PRDM1
Groups	Fold change	Adj. p	Fold change	Adj. p	Fold change	Adj. p	Fold change	Adj. p	Fold change	Adj. p	Fold change	Adj. p
OA-healthy	1.31	0.76	1.17	0.95	1.34	0.54	1.50	0.49	1.23	0.86	1.36	0.68
Arthralgia-healthy	4.55	2.50E-04	24.52	5.34E-04	3.48	2.27E-06	2.97	1.04E-03	2.30	0.11	1.23	0.62
UA-healthy	11.84	3.10E-06	516.33	1.86E-07	4.40	1.00E-05	4.35	4.45E-04	6.96	2.74E-03	4.75	1.18E-03
Early RA-healthy	11.20	3.11E-18	123.34	2.02E-15	3.95	1.79E-15	4.44	2.93E-12	8.42	7.15E-11	3.99	8.37E-09
Est. RA-healthy	8.50	3.03E-17	81.75	3.15E-15	3.83	6.63E-17	3.62	5.14E-11	6.33	8.30E-10	3.31	6.15E-08

OA osteoarthrits, UA undifferentiated arthritis, RA rheumatoid arthritis, Est. established, Adj. adjusted

ISSN: 1478-6362